Rajesh Parekh - Galapagos Non-Executive Chairman of the Board

GLPG -- USA Stock  

Fiscal Quarter End: December 31, 2019  

Dr. Rajesh Parekh was NonExecutive Chairman of the Board of Galapagos NV since July 2004. He is also Chairman of the Company Nomination and Remuneration Committee. He is a General Partner at Advent Life Sciences LLP, which he joined in 2005. During an academic career at Oxford University, he cofounded Oxford GlycoSciences PLC, where he served as Chief Scientific Officer and Chief Executive Officer from 1988 until its sale to Celltech Group PLC in 2003. He has founded or served on the boards of several life sciences companies in the United States and Europe including Celldex Therapeutics, Inc. Avila Therapeutics, Inc. EUSA Pharma Limited Thiakis Limited and Amsterdam Molecular Therapeutics Holding N.V. . Dr. Parekh currently serves as a member of the board of directors of Advent Venture Partners Advent Life Sciences LLP Aleta Inc. Arrakis, Inc. Aura Inc. Artax Inc. Capella BioSciences Ltd. Cellnovo Limited EnCipher Limited Itara Limited Levicept Limited Macrolide Pharmaceuticals, Inc. PE Limited and Project Paradise Limited. He is also a member of the supervisory board of the Novartis Venture Fund. During the past five years, he served as a member of the board of directors of Biocartis NV, 4Antibody AG, NeRRe Therapeutics Limited, F2G Limited, LuxFold S.A., CoCo Therapeutics Limited. He received his MA in Biochemistry and DPhil in Molecular Medicine from the University of Oxford, where he was a Senior Research Fellow and Professor.
Age: 47  Chairman Since 2004      
32 1 534 29 00  http://www.glpg.com

Management Efficiency

The company currently holds 225.92 K in liabilities with Debt to Equity (D/E) ratio of 0.9 which is about average as compared to similar companies. Galapagos NV has Current Ratio of 8.77 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 12 records


David MaddenDicerna Pharmaceuticals
Marc TessierLavignecDenali Therapeutics
Steven GorlinNantKwest
Patrick SoonShiongNantKwest
Richard PilnikDiaMedica Therapeutics
James HealyAuris Medical Holding Ltd
Vernon LoboEquillium
Paul ManningDova Pharmaceuticals
Daniel BradburyEquillium
Arnold OronskyDynavax Technologies Corporatio
Thomas MeyerAuris Medical Holding Ltd

Entity Summary

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. The company was founded in 1999 and is headquartered in Mechelen, Belgium. Galapagos operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 918 people.Galapagos NV (GLPG) is traded on BATS Exchange in USA. It is located in Generaal De Wittelaan L11 A3 and employs 918 people. Galapagos is listed under Pharmaceutical Products category by Fama And French industry classification.

Galapagos NV Leadership Team

Rajesh Parekh, Non-Executive Chairman of the Board
Andre Hoekema, Sr. VP of Corporate Devel.
Katrine Bosley, Independent Non-Executive Director
Walid AbiSaab, Member of the Executive Committee, Chief Medical Officer
Howard Rowe, Non-Executive Independent Director
Harrold Barlingen, Non-Executive Director
Elizabeth Goodwin, VP Corporate Communications & Investor Relations
Mary Kerr, Non-Executive Independent Director
Piet Wigerinck, Chief Scientific Officer
Christine Mummery, Non-Executive Independent Director
Bart Filius, CFO
Onno Stolpe, Co-Founder, CEO, Managing Director and Executive Director
Werner Cautreels, Non-Executive Independent Director

Stock Performance Indicators

Current Sentiment - GLPG

Galapagos NV Investor Sentiment

Most of Macroaxis users are currently bullish on Galapagos NV. What is your judgment towards investing in Galapagos NV? Are you bullish or bearish?
98% Bullish
2% Bearish

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Search macroaxis.com